Raymond Woo, the Chief Technology Officer at Ceribell, Inc. (NASDAQ:CBLL), reported the sale of 11,112 shares of common stock on April 1, 2026, for an aggregate of about $206,243. The sales were completed at a weighted average price between $18.53 and $18.58 per share, effectively in line with the stock 27s recent quoted level of $18.57.
The transaction is recorded in a Form 4 filing with the Securities and Exchange Commission. The same filing discloses that Woo concurrently exercised options to acquire 11,112 shares of common stock at exercise prices ranging from $2.24 to $4.70, representing a total exercise cost of $48,605. In addition to the option exercises, Woo received 30,736 restricted stock units at a zero dollar price.
These insider movements took place against a backdrop of notable share-price appreciation. Over the prior six months the stock had risen approximately 47 percent, according to InvestingPro data. That same platform 27s analysis flagged the stock as currently trading above its Fair Value estimate.
Ceribell, which is valued at $699 million, reported a gross profit margin of 88 percent, a figure that stands out even as the company has not yet achieved overall profitability. The combination of high gross margin and lack of GAAP profits is noted in the filing and contextual materials.
Separately, Ceribell announced that the company received the U.S. Food and Drug Administration Breakthrough Device Designation for its Large Vessel Occlusion, or LVO, stroke detection monitor. The device is intended for hospital use and pairs Ceribell 27s current electroencephalography hardware with an artificial intelligence-driven algorithm designed to interpret brain signals for earlier detection of LVO strokes.
The company highlighted the clinical significance of LVO strokes, noting these events account for a majority of severe post-stroke outcomes - specifically 62 percent of post-stroke dependence and 96 percent of post-stroke mortalities, per the company 27s disclosure. The Breakthrough Device Designation could facilitate a regulatory pathway for the Ceribell System to be positioned as a point-of-care EEG tool aimed at aiding detection and monitoring of LVO strokes in hospital settings. If cleared by the FDA, the company contends the system could enable faster and more accurate stroke diagnoses.
The actions reported in the Form 4 - a stock sale matched by option exercises and the grant of restricted stock units - plus the regulatory update, underscore a period of active insider and corporate developments at Ceribell. The trading activity and corporate disclosures were publicly documented in the filing and company announcement.